Francesca CONRADIE to Middle Aged
This is a "connection" page, showing publications Francesca CONRADIE has written about Middle Aged.
Connection Strength
0,788
-
Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings. JAMA Netw Open. 2024 Jun 03; 7(6):e2415576.
Score: 0,128
-
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 03 05; 382(10):893-902.
Score: 0,096
-
Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):73-78.
Score: 0,088
-
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
Score: 0,088
-
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018 09; 6(9):699-706.
Score: 0,085
-
Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
Score: 0,033
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
Score: 0,033
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
Score: 0,033
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,032
-
Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health. 2022 09; 10(9):e1247-e1256.
Score: 0,028
-
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clin Infect Dis. 2020 01 16; 70(3):436-445.
Score: 0,024
-
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 03 28; 380(13):1201-1213.
Score: 0,022
-
A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLoS One. 2017; 12(5):e0176660.
Score: 0,020
-
Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
Score: 0,019
-
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016 Feb; 47(2):564-74.
Score: 0,018
-
A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS One. 2014; 9(7):e102178.
Score: 0,016
-
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
Score: 0,013
-
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
Score: 0,011